Organic Active Ingredients TRIZ Cases

Heteroaryl amides bind nascent aggregates to prevent neurotoxicity, addressing the lack of effective inhibitors for neurodegenerative diseases.

A chemically defined culture medium optimizes capsular polysaccharide production by precisely controlling nutrient composition.

Pyrrolopyrimidine compounds overcome T790M mutation resistance by selectively targeting mutant EGFR without inhibiting wild-type receptors.

Specific polar lipid ratios prevent age-related muscle loss without pharmaceutical interventions.

Formula A compounds selectively inhibit Nav1.7 channels, avoiding cardiac side effects from non-selective inhibitors.

Amino(meth)acrylate copolymer matrix forms a solid dispersion with antiretroviral active ingredients to enhance solubility and bioavailability.

Pyrrolidinone derivatives target FPR2 receptors to reduce inflammation and prevent adverse remodeling in cardiovascular diseases.

Defined initiation and maintenance cycles of bispecific antibodies reduce relapse rates while minimizing cytokine release syndrome in acute myeloid leukemia.

Administering E-selectin antagonists with venetoclax overcomes microenvironment-mediated resistance in relapsed acute myeloid leukemia patients.

Tocotrienol compositions address limited treatment options by inducing hepatocyte conversion to improve liver histology without worsening fibrosis.

Injectable cell membrane permeable glutathione derivatives bypass poor oral bioavailability to directly elevate intracellular antioxidant levels.

Pivarubicin modifies doxorubicin structure to activate PKC isoforms, inhibiting tumor growth while sparing cardiac tissue from damage.

Replacing toxic acryloyl chloride with acrylamide eliminates contamination issues while maintaining worker safety and improving reaction efficiency.

A cyclic amine derivative inhibits abnormal rises in intraneuronal calcium concentration to treat neuronal hyperexcitability.

A transdermal patch with embedded electrodes delivers electrical stimulation to enhance analgesic absorption through the skin.

Uses betaine and vitamin C combinations to retard cancer progression and treat viral infections.

Fenofibrate beads use surfactants and binders to boost bioavailability despite low water solubility.

A nail lacquer composition uses ciclopirox and film-forming agents to deliver antifungal treatment through the nail plate.

Tadalafil inhibits PRMT5 to reverse Doxorubicin resistance, accelerating clinical translation by repurposing an approved oral drug.

Heterocyclic compounds modulate STING pathway activity to regulate type I interferon production.

Modified oligonucleotides inhibit Notch signaling transcripts to reduce excessive mucus production in respiratory disorders.

Compounds targeting PARP, RNR, and HR repair pathways induce DNA damage in cancer cells.

A bilayer tablet combines immediate-release 5-aminolevulinic acid with sustained-release hydroxychloroquine to treat SARS-CoV-2 infection.

Compound II enhances oxidative phosphorylation and exercise tolerance in mammals with primary mitochondrial myopathies lacking effective therapies.

A palbociclib succinate solid dosage form maintains dissolution profiles through water-soluble acid integration.

Novel carbamoyloxy arylalkanoyl arylpiperazine compounds target serotonin receptors to treat multiple conditions.

Viral vectors restore FHIT expression in malignant cells to suppress tumorigenesis while managing gene therapy process complexity.

Prodrug compounds convert to active integrase inhibitors in vivo, bypassing resistance mechanisms that limit current treatment efficacy.

ADH, AKR, and SNO-CoAR inhibitors reduce LDL-C and triglycerides without gastrointestinal side effects.

Aliphatic alcohol solvents enable mild pressure hydrogenation, reducing apparatus complexity while maintaining high product purity.

Segmented compounds target ALK5 selectively to reduce toxicity while maintaining therapeutic efficacy.

Formula I compounds inhibit BET bromodomains, addressing the complexity of developing selective therapies for cancer and inflammatory diseases.

Specific bacteria and prebiotics alter gut microbiota composition to overcome immune checkpoint inhibitor resistance.

A regenerative peritoneal dialysis system uses a sterilization module to purify fluid on demand.

A buccal taxane composition uses mucoadhesive polymers to deliver drugs directly into the bloodstream.

A pyridine carboxamide compound treats brain trauma via targeted PDE4 inhibition.

Oral transmucosal compositions deliver aromatase inhibitors directly into the bloodstream through the oral mucosa.

Combining DUOC-01 cell product with hydrocortisone enhances cell viability and promotes remyelination in demyelinating conditions.

MicroRNA 106b restores adult cardiomyocyte proliferative potential to replace infarct scar tissue with functional contractile myocardium.

Cyclicmorphinan derivatives modulate specific opioid receptors to reduce central side effects while maintaining analgesic efficacy.

Edoxaban tosylate hydrate tablet balances hardness with rapid disintegration by optimizing excipient ratios to resolve mechanical strength trade-offs.

Bioactive small molecules trigger rapid peptide self-assembly into supramolecular hydrogels, bypassing slow enzymatic processes.

An adhesive patch integrates local anesthetic and dimethyl sulfoxide to deliver medication directly through the skin.

Cyclodextrins encapsulate meloxicam in inclusion complexes, resolving poor solubility and delayed onset of pain relief.

Agar-agar and pectin matrices stabilize hydrophobic vitamin D, resolving aqueous solubility issues.

3-Azabicyclo[3.2.1]octan derivatives modulate p38 MAPK and JNK kinases via MKP-1 accumulation.

A Lazertinib pharmaceutical composition utilizes a cellulose derivative and polyol diluent system to enhance manufacturability and stability.

Replacing costly PEGylation, these biodegradable polypeptides extend plasma half-life while avoiding immunogenicity and manufacturing complexity.

Synthesized ((R)-4-(2-hydroxy-5-methylphenyl)-5-methylhexanoic acid counters MPP+ toxicity to prevent neural degeneration.

Segmented bridged piperazine pyrimidopyran compounds inhibit KRAS G12D mutations, addressing the lack of effective precision medicine options.

Modified USH2A oligonucleotides skip deleterious exons to restore usherin protein activity and improve vision efficacy.

Crystalline forms and salts of phosphonooxymethyl oxime pregnenedione provide enhanced solubility and stability for pharmaceutical compositions.

Small molecule CD73 antagonist reduces extracellular adenosine to reverse immunosuppression and prevent drug resistance during cancer therapy.

Merges SRB1 antibody, vincristine, and dexamethasone to extend median survival time in T-ALL and pancreatic cancer models.

Tricyclic compounds block mitochondrial apoptosis-induced channel opening, preventing cytochrome c release and neuronal loss in neurodegenerative diseases.

Derivatized Leptomycin B compounds reduce gastrointestinal toxicity while maintaining antitumor activity through selective Crm1 inhibition.

A pH-dependent coating delays cholestyramine release in the colon, reducing drug interactions and constipation.

A hydrocolloid dressing sustains hydrogen sulfide release, preventing cytotoxicity and improving chronic wound healing.

Dihydroquinazolinone compounds inhibit tankyrase and microtubules, addressing insufficient activity of existing inhibitors in treating proliferative diseases.

Ammonium hydroxide extraction isolates neosaxitoxin from cyanobacterial biomass, resolving the trade-off between high yield and retained biological activity.

Modifying molecular parameters of PI4K inhibitors reduces CYP3A4 inhibition to prevent drug-drug interactions while maintaining antiviral activity.

Azetidine compounds target peripheral CB1 receptors to reduce obesity while avoiding central nervous system psychotropic side effects.

Immobilized antibodies remove sVEGFR-1 and sVEGFR-2 to delay premature delivery.

SELEX-selected aptamers achieve high-affinity binding to CD3 proteins, resolving the contradiction between specificity and efficiency in T cell isolation.

A solid pharmaceutical composition blends an aromatase inhibitor with excipients to achieve uniform distribution within capsules.

Oligonucleotide aptamers bind microvesicle surface antigens and complement C1q subunits, resolving low diagnostic specificity in cancer detection.

Topical brimonidine application protects hair follicles from chemotherapy damage, replacing uncomfortable scalp hypothermia methods.

PROTAC compounds degrade ERK5 kinase, eliminating paradoxical activation and non-specific effects seen with traditional inhibitors.

Genetic testing detects androgen receptor F876L modifications to identify therapeutic resistance.

U1 adaptors inhibit polyadenylation by tethering snRNPs to pre-mRNA, resolving modest downregulation limits in RNAi.

Novel amphiphilic copolymers replace PEG to eliminate hypersensitivity while maintaining drug solubility and in vivo stability.

A CD38 antibody binds the protein with high affinity to trigger tumor cell destruction.

Formula I heterocyclic compounds inhibit CD73 to control tumor growth and metastasis in cancer treatment.

A thermodynamically stable crystalline form of the orexin receptor antagonist ACT-539313 improves solid dosage manufacturing.

A Cutibacterium acnes cell wall conjugate with mucopolysaccharides neutralizes extracellular vesicle toxins to restore physiological microbiota balance.